Phase 2 N=15 Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis
Total Laryngectomy
Primary: Short-term Feasibility Provox Vega 22.5 French — 15 Patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=33 Long Term Use of the Provox Vega 22.5
Total Laryngectomy
Primary: Patient Preference — 14; 7; 11 Patients
Phase 2 N=38 NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia
Leukemia, Lymphocytic, Acute
Primary: Toxicity of Treatment in Terms of Number of Participants With Serious Adverse Events or Adverse Events, Reported — 26 Participants
Phase 2 N=80 Testing Methylphenidate for Smoking Abstinence
Smoking
Primary: Number of Subjects Biochemically Confirmed to be Abstinent From Smoking at End of Treatment. — 1; 4 participants — p=0.973
Phase 2 N=200 A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children
Healthy
Primary: Percentage of Participants Who Shed Any Vaccine Virus — 88.9; 69.0 percentage of participants
Phase 2 N=18 An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters
Colonoscopy · Bowel Preparation
Primary: Maximum Observed Concentration (Cmax) — 717.0; 499.5; 560.2 µmol/L
Phase 2 N=260 Leprosy Skin Test Antigens Trial
Leprosy
Primary: Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram — 0; 3; 1; 5…
Phase 2 N=564 The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
Metabolism and Nutrition Disorder · Obesity
Primary: Mean Change From Baseline in Body Weight at Week 20 — 97.3; 96.4; 98.0; 98.4 kg
Phase 2 N=92 Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage
Abscess · Cellulitis
Primary: Number of Participants Who Experienced a 30% or Greater Reduction in Surface Area of Abscess — 6; 19 Participants — p=.0003
Phase 2 N=382 Safety and Tolerability of Buprenorphine/Naloxone Film Strips
Opioid-Related Disorders
Primary: Number of Subjects With Treatment-emergent Adverse Events Associated With the Oral Cavity. — 11; 16 Participants
Phase 2 N=63 Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer · Chemotherapy-Induced Thrombocytopenia · Non-Small Cell Lung Cancer
Primary: Number of Participants With Adverse Events — 12; 16; 18; 14 Participants
Phase 2 N=63 Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
Tourette Syndrome
Primary: Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale — -7.17; -7.16 score on a scale — p=0.996
Phase 2 N=54 A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Percentage of Participants Surviving at 6 Months — 57.4 percentage of participants
Phase 2 N=64 Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma
Follicular Lymphoma
Primary: Progression-free Survival — 59 percent chance of PFS at 5 years
Phase 2 N=8 A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)
Schizophrenia · Schizoaffective Disorder
Primary: Pharmacokinetic Parameter of Maximum Plasma Concentration (Cmax) of Two Differing Tablet Strengths (3 x 5 mg and 1 x 15 mg) of Sublingually Administered Org 5222…